Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
作者信息
Mateos Maria-Victoria, Orlowski Robert Z, Ocio Enrique M, Rodríguez-Otero Paula, Reece Donna, Moreau Philippe, Munshi Nikhil, Avigan David E, Siegel David S, Ghori Razi, Farooqui Mohammed Z H, Marinello Patricia, San-Miguel Jesus
机构信息
Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC-CSIC-USAL), Salamanca, Spain.
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.
PMID:31090915
Abstract
摘要
Zotero 插件